Christine Curcio PhD. Macregen's Chief Scientific Officer, publishes seminal AMD paper in Investigative Ophthalmology and Visual Science (IOVS).

Macregen, Inc. is pleased to announce the appointment of Professor Robert Scott MD as  Principal Consultant for Topical Drug Delivery. Please see Dr. Scott's biosketch on the Macregen Team page.

Interview with Robert Scott MD. Macregen's principal consultant for topical drug delivery

B. Michael Silber PhD. Macregen's President and Chief Executive Officer talks about and introduces Macregen Inc., Age-Related Macular Degeneration, and Mitia™.

Keith Roizman, Macregen Inc. Executive Chairman and Chief Technology Officer discusses the OPHTHAMIZE™ Program for treating AMD and other eye diseases.